Showing 3611-3620 of 5089 results for "".
- FDA Grants Orphan Drug Designation for Galderma's Trifarotene Molecule to Treat Congenital Ichthyosishttps://practicaldermatology.com/news/20140702-fda_grants_orphan_drug_designation_for_galdermas_trifarotene_molecule_to_treat_congenital_ichthyosis/2459180/The FDA granted orphan drug designation status for Galderma's trifarotene molecule for the treatment of congenital ichthyosis. Based on this decision, Galderma says it pla
- FDA Issues Guidance Supporting the Responsible Development of Nanotechnology Productshttps://practicaldermatology.com/news/20140625-fda_issues_guidance_supporting_the_responsible_development_of_nanotechnology_products/2459190/Three final guidances and one draft guidance were issued by the U.S. Food and Drug Administration providing greater regulatory clarity for industry on the use of nanotechnology in FDA-regulated products. Nanotechnology is an emerging technology allowing scientists to create, explore, and
- Envy Medical Receives Growth Capital Investment from HCP & Companyhttps://practicaldermatology.com/news/20140604-envy_medical_receives_growth_capital_investment_from_hcp__company/2459218/Chicago-based HCP & Company is providing a growth capital investment to Envy Medical to support sales and marketing initiatives, while also allowing the company to accelerate the development and introduction of new skincare offerings designed to meet the growing demand for healthier skin tone, te
- Cetaphil Launches the Gentle Power Campaignhttps://practicaldermatology.com/news/20140602-cetaphil_launches_the_gentle_power_campaign/2459221/The new Gentle Power Campaign for Cetaphil brands (Galderma) showcases the brand's products and demonstrates how women balance the demands of their day-to-day lives, just as Cetaphil products balance the daily demands on their skin. Stuart Raetzman, chief executive officer of Galderma L
- Two Gene Mutations Linked to Melanoma of the Eyehttps://practicaldermatology.com/news/20140602-two_gene_mutations_linked_to_melanoma_of_the_eye/2459222/Researchers have elucidated mechanisms of two gene mutations associated with uveal melanoma, identified a therapeutic target for treating uveal melanoma in adults, and provided evidence that an existing therapy can be used to slow eye tumor growth. The presence of one of two gene mutation
- derma e Scar Gel Proves Effective in Clinical Trialhttps://practicaldermatology.com/news/20140502-derma_e_scar_gel_proves_effective_in_clinical_trial/2459247/The results of an independent clinical trial on derma e Scar gel formula proved the formula effective for participants who used the product for an eight-week period. Derma e Scar gel is a naturally therapeutic treatment that is designed to smooth, soften, and decrease the look of
- XOMA Finalizes Gevokizmab Phase III Clinical Program in Pyoderma Gangrenosumhttps://practicaldermatology.com/news/20140428-xoma_finalizes_gevokizmab_phase_3_clinical_program_in_pyoderma__gangrenosum/2459254/Xoma Corporation finalized the plans for gevokizumab Phase III Program in Pyoderma Gangrenosum (PG). The Phase III Study will include two double-blind placebo-controlled clinical studies with 60 patients who have active PG. Paul Rubin, Senior Vice President,
- Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lineshttps://practicaldermatology.com/news/20140421-revance_therapeutics_announces_positive_results_from_the_rt002_phase_12_study_in_glabellar_frown_lines/2459262/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorpo
- Merz North American Provides Educational Grant to Support Dermatology Board Review Systemhttps://practicaldermatology.com/news/20140327-merz_north_american_provides_education_grant_to_support_dermatology_board_review_system/2459291/Merz North America recently provided an educational grant to fund the Derm In-Review system that helps residents prepare for their Board certifying exams free of charge. The system, which has helped prepare more
- Joseph R. Williams Becomes Vice President of Global Marketing for Caliber Imaging & Diagnosticshttps://practicaldermatology.com/news/20140326-joseph_r_williams_becomes_vice_president_of_global_marketing_for_caliber_imaging__diagnostics/2459292/Caliber Imaging & Diagnostics named Joseph R. Williams Vice President of Global Marketing. Williams past experience led him to this new position. Previously, he was Director of Market Development at AxsunTechnologies/Volcano Corporation, Senior Director of Global Marketing-Neurosurgery Di